PLUS THERAPEUTICS found using ticker (PSTV) now have 2 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 6 and 5.25 and has a mean target at 5.63. Given that the stocks previous close was at 2.14 this would indicate that there is a potential upside of 163.1%. The 50 day moving average now sits at 2.13 and the 200 moving average now moves to 2.41. The market cap for the company is $10m. Find out more information at: http://www.plustherapeutics.com
Plus Therapeutics, a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. Its lead product candidate is DocePLUS, a protein-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. The company is also involved in developing DoxoPLUS, a generic PEGylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and Kaposi’s sarcoma. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx’s glioblastoma treatment. The company was formerly known as Cytori Therapeutics and changed its name to Plus Therapeutics in July 2019. Plus Therapeutics was founded in 1996 and is headquartered in Austin, Texas.